News › GlobeNewswire Inc.

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

GlobeNewswire Inc. • Jan 6, 2026 6:00am (New York) •By Not Specified

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Aclarion announced that Northwestern Medicine and Scripps Health have enrolled their first patients in the CLARITY pivotal trial, bringing the total to four sites with patient enrollments. Seven clinical sites have completed regulatory requirements and are ready to enroll. The company expects initial data readout in Q3 2026 after the first cohort completes 3-month follow-up visits. The trial aims to demonstrate that Nociscan improves surgical outcomes for chronic low back pain beyond the current 54% industry benchmark.

← Back to news Read Original Article

Insights

NKE negative

Mentioned as struggling with footwear and apparel market challenges.

ACON positive

The company announced significant progress on its pivotal CLARITY trial with enrollment at multiple leading medical centers, hired key commercial personnel to drive expansion, and provided a clear timeline for interim data results. These milestones represent meaningful advancement toward generating clinical evidence and supporting future reimbursement discussions, which are critical value drivers for the company.

Keywords

#CLARITY trial #Nociscan #chronic low back pain #clinical trial enrollment #patient outcomes #spine surgery #biomarkers #MRI spectroscopy

Tickers

ACON ACONW

← Prev: Nordics Colocation Data Center Portfolio Report 2025-2029: Detailed Analysis of 134 Existing Data Centers, 71 Upcoming Data Centers, and 79 Major Operators/Investors

Next: Short-Term Skepticism Persists Despite Copper's Explosive Start →